Company Overview and News

 
Asoka Sirisena re-elected President of Sri Lanka Insurance Institute

2018-09-06 lankabusinessonline
Sept 06, 2018 (LBO) – Asoka Sirisena,senior deputy general manager, technical of Ceylinco Life Insurance Limited was re-elected as the President for 2018/2019 at the recently held annual general meeting of the Sri Lanka Insurance Institute (SLII).
UAL

 
Asia Securities Chairman Dumith Fernando appointed to Union Assurance (UAL) Board

2018-08-03 lankabusinessonline
August 3, 2018 (LBO) – Asia Securities Chairman has been appointed as an Independent Non-Executive Director of CSE listed insurance company Union Assurance (UAL).
UAL

 
UAL only Sri Lankan company in Forbes Asia’s 200 ‘Best under a Billion’ 2018 list

2018-07-30 lankabusinessonline
Jul 30, 2018 (LBO) – Sri Lanka’s Union Assurance PLC, a life insurance provider has made it to Forbes Asia’s 2018 list of ‘Best under a Billion ‘ list of the top 200 publicly listed companies in the Asia-Pacific region.
GRAPHITE UAL 509488

 
Depressed consumer demand hampers John Keells first quarter

2018-07-30 dailymirror.lk
John Keells Holdings PLC (JKH), Sri Lanka’s highest valued business conglomerate, could not escape from the dampened economic activities in the country, as the group performance was hampered by its key consumer business segments.
JKL JKELF JKH UAL NTB JKEHY

 
Sri Lanka’s JKH Group PBT up 21-pct to Rs.27.6Bn

2018-05-31 lankabusinessonline
John Keells Group profit before tax (PBT) increased by 21% to Rs.27.63 billion for the financial year ended 31 March 2018. The profit attributable to equity holders of the parent was Rs.21.02 billion, representing an increase of 29% over the Rs.16.28 billion recorded in the previous year
UAL

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to CSE:UAL / UNION ASSURANCE PLC on message board site Silicon Investor.

Qualcomm Moderated Thread - please read rules before posting Qualcomm Moderated Thread - please read rules before posting Qualcomm Moderated Thread - please read rules before posting The New QUALCOMM - Coming Into Buy Range The New QUALCOMM - Coming Into Buy Range The New QUALCOMM - Coming Into Buy Range
The New Qualcomm - write what you like thread. The New Qualcomm - write what you like thread. The New Qualcomm - write what you like thread. NXPI after Qualcomm failed bid NXPI after Qualcomm failed bid NXPI after Qualcomm failed bid
Virtual Reality Virtual Reality Virtual Reality Qualcomm Incorporated (QCOM) Qualcomm Incorporated (QCOM) Qualcomm Incorporated (QCOM)
Genomic Health: predicting the course of an individualu0027s can Genomic Health: predicting the course of an individualu0027s can Genomic Health: predicting the course of an individualu0027s can Vanguard Mutual Funds Vanguard Mutual Funds Vanguard Mutual Funds
Actual left/right wing discussion Actual left/right wing discussion Actual left/right wing discussion Vanuard Mutual Funds Vanuard Mutual Funds Vanuard Mutual Funds